Showing results (121-130 of 140) with videos related to

Sort By:
Pageof 14
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 18, 2021
Venetoclax in Previously Treated Waldenström MacroglobulinemiaJorge J Castillo, John N Allan, Tanya Siddiqi, et al.
Blood|December 27, 2019
Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 resultsJohn C Byrd, William G Wierda, Anna Schuh, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 10, 2008
Persistent and relapsing babesiosis in immunocompromised patientsPeter J Krause, Benjamin E Gewurz, David Hill, et al.
Blood|January 15, 2016
Postibrutinib outcomes in patients with mantle cell lymphomaPeter Martin, Kami Maddocks, John P Leonard, et al.
The Lancet. Haematology|December 24, 2019
Acalabrutinib monotherapy in patients with Waldenström macroglobulinemia: a single-arm, multicentre, phase 2 studyRoger G Owen, Helen McCarthy, Simon Rule, et al.
The Lancet. Haematology|May 22, 2019
Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validationsJacob D Soumerai, Ai Ni, Mohamed Darif, et al.
NEJM Evidence|February 6, 2024
Zilovertamab Vedotin Targeting of ROR1 as Therapy for Lymphoid CancersMichael L Wang, Jacqueline C Barrientos, Richard R Furman, et al.
The Journal of Clinical Investigation|September 26, 2023
Hyperphosphorylation of BCL-2 family proteins underlies functional resistance to venetoclax in lymphoid malignanciesStephen Jun Fei Chong, Fen Zhu, Olga Dashevsky, et al.
Blood|March 7, 2009
Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports projectKenneth R Carson, Andrew M Evens, Elizabeth A Richey, et al.
Leukemia|July 21, 2021
Polygenic risk score and risk of monoclonal B-cell lymphocytosis in caucasians and risk of chronic lymphocytic leukemia (CLL) in African AmericansGeffen Kleinstern, J Brice Weinberg, Sameer A Parikh, et al.
Pageof 14